Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink: If clicking on the above link does not open up a new web page, you may need to cut and paste the above URL into your browser's address bar.) For additional details, see the associated financial schedules and product revenue tables attached to the press release located at the hyperlink referred to above and the attached disclosure notice. Reported net income is defined as net income attributable to Pfizer Inc. See the accompanying reconciliations of certain GAAP Reported to non-GAAP Adjusted information for the fourth quarter and twelve months ended 20, as well as reconciliations of full-year 2016 guidance for Adjusted income and Adjusted diluted EPS to full-year 2016 guidance for Reported net income For a description of the revenues in each business, see the “Our Strategy––Commercial Operations” sub-section in the Overview of Our Performance, Operating Environment, Strategy and Outlook section of Pfizer's Quarterly Report on Form 10-Q for the fiscal quarter ended September 27, 2015.
Reported revenues is defined as revenues in accordance with U. Other includes revenues from Pfizer Centre Source, our contract manufacturing and bulk pharmaceutical chemical sales organization, and revenues related to our manufacturing and supply agreements with Zoetis Inc.
We believe the completion of the Hospira acquisition and the pending Allergan combination will strengthen our core businesses and better position the Company for sustainable revenue growth in the future.
The Innovative Products business is composed of two operating segments: the Global Innovative Pharmaceutical segment (GIP), which includes all legacy Hospira commercial operations.
Financial results for each of these segments are presented in the Operating Segment Information section.
(Baxter) of $35 million, Pfizer-standalone revenues increased by $646 million operationally, or 5%.
Operational revenue growth in developed markets was driven primarily by the inclusion of $1.1 billion of revenues from legacy Hospira operations and continued strong performance of several key products, notably Prevnar 13 in adults and Ibrance in the U.
These planned repurchases are expected to more than offset the potential dilution related to employee compensation programs,” Mr. QUARTERLY FINANCIAL HIGHLIGHTS (Fourth-Quarter 2015 vs. Fourth-Quarter 2014) Reported revenues totaled $14.0 billion, an increase of $930 million, or 7%, which reflects operational growth of $1.9 billion, or 14%, partially offset by the unfavorable impact of foreign exchange of $934 million, or 7%.